Form 4: VolitionRx Director Guy Innes Boosts Stake with Significant Share Purchase

VolitionRx Ltd. Director Guy Archibald Innes has increased his direct beneficial ownership in the company by purchasing 20,000 shares of common stock at $0.5386 per share.

Summary

• Guy Archibald Innes, a Director of VolitionRx Ltd. (VNRX), purchased 20,000 shares of the company's common stock.
• The transaction occurred on June 3, 2025, at a price of $0.5386 per share, totaling $10,772.00.
• Following this transaction, Mr. Innes directly beneficially owns 888,689 shares of common stock.
• Additionally, Mr. Innes has indirect beneficial ownership of 1,400,000 shares through The Innes Family Bare Trust 2023, 356,000 shares through The Dill Faulkes Educational Trust Limited, and 618,014 shares through his children (two sons and two daughters).
• His total beneficial ownership, direct and indirect, now stands at 3,267,703 shares.

Sentiment

Score: 8

Explanation: The purchase of shares by a director is a strong positive signal, indicating confidence in the company's future. The size of the purchase relative to the director's existing holdings and the company's market cap would further refine this, but generally, insider buying is bullish.

Positives

• The purchase of 20,000 shares by a company director signals confidence in the company's future prospects and valuation.
• An insider increasing their stake aligns their interests more closely with those of other shareholders.

Negatives

• No negative aspects are directly indicated by this insider purchase transaction.

Risks

• The Form 4 filing itself does not detail specific company risks; it reports an insider transaction.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider purchases, such as this one, are generally viewed positively by the market as they indicate management's belief in the company's intrinsic value and future performance, often signaling undervaluation or strong future prospects relative to industry peers.

Comparison to Industry Standards

• This document reports an insider transaction, which is a standard regulatory disclosure. Direct comparisons to specific companies or projects are not applicable as the filing focuses on an individual's shareholding rather than operational or financial performance against industry benchmarks.

Related Party Transactions

• The reporting person disclaims beneficial ownership of shares held by The Dill Faulkes Educational Trust Limited except to the extent of his pecuniary interest therein, despite serving as a director and trustee with shared voting and dispositive control.
• Shares are beneficially owned by The Innes Family Bare Trust 2023, for which the reporting person is the Trustee for the benefit of his children.
• Shares are indirectly beneficially owned by the reporting person's sons and daughters.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator, potentially increasing investor confidence and demand for the stock.
• The transaction aligns the director's financial interests more closely with those of the company's shareholders.

Next Steps

• The document does not outline specific future actions, events, or milestones for the company, as it is a report of a past transaction.

Key Dates

Recommendation

Keywords

VolitionRx, VNRX, Insider Trading, Form 4, Share Purchase, Director, Equity, Beneficial Ownership, SEC Filing